Lynronne-1, an antimicrobial peptide, exhibits activity against Gram-positive bacteria, including multi-drug resistant (MDR) strains, with a minimal inhibitory concentration (MIC) of 8-32 μg/mL for methicillin-resistant MRSA strains. Additionally, it effectively reduces the bacterial load in a murine model of MRSA-infected wounds and demonstrates efficacy against P. aeruginosa infections [1].